Telehealth boomed during the pandemic, and experts believe that even with the world opening back up, pharma companies will have to continue to shift and strengthen tactics to reach physicians and patients virtually.
Greater Than One Chief Technology Officer Ken Winell explores and offers considerations to how innovation and changes in telemedicine can fit comfortably, and successfully, into the U.S. healthcare ecosystem.
The impact of the global pandemic has been felt across all facets of life, including medical care. Telehealth, which was already gaining in popularity, received a major boost as a result of COVID: Before the pandemic, 56 percent of Americans did not believe they could receive the same level of care from telehealth compared to in-person care, but recent polling shows nearly 80 percent of Americans now say it is possible.
Although the endocannabinoid system has been intensely studied, there are still few drugs approved or in development that interact with it.
Yuval Cohen, Ph.D., CEO of Corbus Pharmaceuticals Holdings, spoke with Med Ad News about what the endocannabinoid system is, Corbus’ pipeline of drugs, and why he thinks there will be a flood of drugs targeting the endocannabinoid system.
Pharma’s Class of 2019 is making the rare beware. Four of the top six 2019 drug launches based on 2020 sales target rare diseases.
Med Ad News talked to the management team of LevLane about the process of building best brands, key factors in producing a successful brand launch, navigating the launch of new products and campaigns with clients during the COVID-19 pandemic, and other topics.
As COVID restrictions roll back, business leaders are peeking out of their foxholes, wondering if it’s safe to bring the troops back to headquarters. It’s a fair question – to which, one might answer, “Sure, but what’s the rush?”
Too often, Washington decision makers ignore the importance of informing healthcare practitioners (HCPs) and patients about therapeutic innovations. Perhaps that’s why they find it so hard to let go of “feel good” ideas intended as tools to limit healthcare communications, especially direct-to-consumer (DTC) promotion.
Humira could generate more than $20 billion in sales for AbbVie during 2021 while Merck’s Keytruda is on track to become only the second prescription medicine ever to exceed $16 billion in annual sales.